Loading...
•
Jun 30, 2025
Minerva Neurosciences Q2 2025 Earnings Report
Minerva Neurosciences reported a narrower net loss in Q2 2025 due to significantly reduced R&D and G&A expenses, and recorded no non-cash interest expense during the quarter.
Key Takeaways
Minerva Neurosciences posted a net loss of $3.26 million in Q2 2025, driven by lower spending as the company evaluates strategic alternatives following FDA's requirement for a confirmatory study of roluperidone.
Net loss decreased to $3.3 million from $8.2 million in Q2 2024.
R&D expenses dropped significantly year-over-year to $1.3 million.
No non-cash interest expense was recorded this quarter compared to $2.3 million last year.
Cash and equivalents totaled $15.3 million, with a $60 million royalty-related liability.
Forward Guidance
Minerva plans to initiate a confirmatory Phase 3 trial of roluperidone while evaluating strategic options to maximize shareholder value.
Positive Outlook
- FDA accepted proposal for monotherapy confirmatory trial.
- No requirement for adjunctive trial with antipsychotics.
- Clear regulatory path outlined for NDA resubmission.
- Trial design includes well-defined endpoints and safety metrics.
- Cost control measures have reduced quarterly burn.
Challenges Ahead
- FDA requires a new 52-week confirmatory trial before NDA resubmission.
- No product revenues generated in the quarter.
- Royalty sale liability remains at $60 million.
- Stockholders’ equity remains negative.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...